In summary, this study proposes NB54 as a potential new therapeutic agent for RTT nonsense mutations, and in so doing supports the “proof of principle” that some RTT causative MECP2 nonsense mutations can be at least partially suppressed by less toxic aminoglycosides and aminoglycoside mimetics. The gene discussed is MECP2; the disease is Rett syndrome.